JP Morgan Chase
ELDN icon

JP Morgan Chase’s Eledon Pharmaceuticals ELDN Stock Holding History

JP Morgan Chase’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125K Buy
32,311
+1,948
+6% +$7.08K ﹤0.01% 5892
2026
Q1 		$82.3K Buy
30,363
+7,921
+35% +$18.7K ﹤0.01% 5937
2025
Q4 		$33.9K Sell
22,442
-249
-1% -$592 ﹤0.01% 6370
2025
Q3 		$58.8K Sell
22,691
-5,007
-18% -$14.6K ﹤0.01% 6170
2025
Q2 		$75.1K Buy
+27,698
New +$83.1K ﹤0.01% 5737
2024
Q4 		– Sell
-97
Closed -$242 – 7462
2024
Q3 		$242 Buy
97
+6
+7% +$16 ﹤0.01% 6883
2024
Q2 		$240 Buy
91
+35
+63% +$84 ﹤0.01% 6765
2024
Q1 		$115 Sell
56
-934
-94% -$1.67K ﹤0.01% 6883
2023
Q4 		$1.78K Buy
990
+964
+3,708% +$1.34K ﹤0.01% 6738
2023
Q3 		$36 Buy
+26
New +$35 ﹤0.01% 7050
2021
Q4 		– Sell
-20
Closed – – 6719
2021
Q3 		$0 Sell
20
-46
-70% -$322 ﹤0.01% 6550
2021
Q2 		$1K Buy
+66
New +$623 ﹤0.01% 6244
2020
Q2 		– Sell
-6
Closed – – 5451
2020
Q1 		$0 Buy
+6
New +$57 ﹤0.01% 5392
2017
Q2 		– Sell
-660
Closed -$89K – 5017
2017
Q1 		$89K Sell
660
-49
-7% -$7.2K ﹤0.01% 4365
2016
Q4 		$112K Buy
709
+77
+12% +$14.8K ﹤0.01% 4370
2016
Q3 		$157K Buy
632
+31
+5% +$11.3K ﹤0.01% 3756
2016
Q2 		$537K Sell
601
-12
-2% -$13.2K ﹤0.01% 3410
2016
Q1 		$557K Buy
613
+26
+4% +$25.5K ﹤0.01% 3312
2015
Q4 		$828K Sell
587
-583
-50% -$1.02M ﹤0.01% 3193
2015
Q3 		$1.96M Buy
1,170
+93
+9% +$192K ﹤0.01% 2758
2015
Q2 		$2.32M Sell
1,077
-101
-9% -$195K ﹤0.01% 2823
2015
Q1 		$2.16M Sell
1,178
-30
-2% -$66.2K ﹤0.01% 2823
2014
Q4 		$2.88M Sell
1,208
-19
-2% -$45.1K ﹤0.01% 2745
2014
Q3 		$3.01M Buy
+1,227
New +$3.49M ﹤0.01% 2665

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

JP Morgan Chase's ELDN Position: Q2 2026 in Review

JP Morgan Chase increased its Eledon Pharmaceuticals (ELDN) stake by 6.4% in Q2 2026, buying an estimated $7.08K and bringing the position to 32,311 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #5892.

JP Morgan Chase first reported a position in ELDN in Q3 2014 and has held it in 24 quarters since. The position peaked at $3.01M in Q3 2014. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • JP Morgan Chase held 32,311 shares of Eledon Pharmaceuticals worth $125K as of Q2 2026.
  • JP Morgan Chase bought 1,948 Eledon Pharmaceuticals shares in Q2 2026, an estimated $7.08K.
  • Eledon Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5892 holding.
  • JP Morgan Chase first reported a position in Eledon Pharmaceuticals in Q3 2014 and has held it in 24 quarters since.
  • JP Morgan Chase's Eledon Pharmaceuticals position peaked at $3.01M in Q3 2014.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.